Show simple item record

dc.contributor.authorEason, K
dc.contributor.authorSadanandam, A
dc.date.accessioned2017-07-20T10:13:54Z
dc.date.issued2016-09
dc.identifier.citationCancer research, 2016, 76 (18), pp. 5195 - 5200
dc.identifier.issn0008-5472
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/734
dc.identifier.eissn1538-7445
dc.identifier.doi10.1158/0008-5472.can-16-0141
dc.description.abstractTumor heterogeneity is reflected and influenced by genetic, epigenetic, and metabolic differences in cancer cells and their interactions with a complex microenvironment. This heterogeneity has resulted in the stratification of tumors into subtypes, mainly based on cancer-specific genomic or transcriptomic profiles. Subtyping can lead to biomarker identification for personalized diagnosis and therapy, but stratification alone does not explain the origins of tumor heterogeneity. Heterogeneity has traditionally been thought to arise from distinct mutations/aberrations in "driver" oncogenes. However, certain subtypes appear to be the result of adaptation to the disrupted microenvironment caused by abnormal tumor vasculature triggering metabolic switches. Moreover, heterogeneity persists despite the predominance of single oncogenic driver mutations, perhaps due to second metabolic or genetic "hits." In certain cancer types, existing subtypes have metabolic and transcriptomic phenotypes that are reminiscent of normal differentiated cells, whereas others reflect the phenotypes of stem or mesenchymal cells. The cell-of-origin may, therefore, play a role in tumor heterogeneity. In this review, we focus on how cancer cell-specific heterogeneity is driven by different genetic or metabolic factors alone or in combination using specific cancers to illustrate these concepts. Cancer Res; 76(18); 5195-200. ©2016 AACR.
dc.formatPrint
dc.format.extent5195 - 5200
dc.languageeng
dc.language.isoeng
dc.rights.urihttps://www.rioxx.net/licenses/all-rights-reserved
dc.subjectAnimals
dc.subjectHumans
dc.subjectNeoplasms
dc.subjectGenotype
dc.subjectPhenotype
dc.titleMolecular or Metabolic Reprograming: What Triggers Tumor Subtypes?
dc.typeJournal Article
dcterms.dateAccepted2016-05-05
rioxxterms.versionofrecord10.1158/0008-5472.can-16-0141
rioxxterms.licenseref.urihttps://www.rioxx.net/licenses/all-rights-reserved
rioxxterms.licenseref.startdate2016-09
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfCancer research
pubs.issue18
pubs.notesNo embargo
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Systems and Precision Cancer Medicine
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Systems and Precision Cancer Medicine
pubs.publication-statusPublished
pubs.volume76
pubs.embargo.termsNo embargo
icr.researchteamSystems and Precision Cancer Medicineen_US
dc.contributor.icrauthorSadanandam, Angurajen
dc.contributor.icrauthorEason, Katherineen


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record